🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

KeyBanc sustains Emerson shares at Overweight on sales increase

EditorNatashya Angelica
Published 11/05/2024, 10:45 AM
EMR
-

On Tuesday, KeyBanc Capital Markets maintained its Overweight rating on shares of Emerson Electric Co. (NYSE:EMR) with a steady price target of $125.00. Emerson reported a quarterly net sales increase of 13% year-over-year on a pro-forma basis, totaling $4.619 billion, surpassing both the consensus estimate of $4.566 billion and KeyBanc's projection of $4.563 billion.

Earnings per share (EPS) for the quarter came in at $1.48, slightly above the consensus of $1.47 and KeyBanc's estimate of $1.46. The company experienced a 4% rise in underlying sales, also referred to as organic growth, and a 2% increase in underlying orders year-over-year.

Emerson's adjusted segment EBITA margin was reported at 26.2%, which is higher than both the consensus of 26.0% and KeyBanc's estimate of 25.4%, marking a 60 basis point increase from the previous year. The company's backlog, excluding AspenTech, now stands at $7.20 billion, a slight decrease from $7.40 billion in the previous quarter.

Furthermore, Emerson's strategic project growth funnel has increased to $11.2 billion, up from $11.0 billion in the last quarter, indicating a growing pipeline of potential future business. KeyBanc's reaffirmed rating and price target reflect the firm's continued confidence in Emerson's financial performance and business prospects.

In other recent news, Emerson has experienced a series of significant developments. The company's full-year adjusted earnings per share (EPS) guidance has been raised to $5.45 to $5.50 and free cash flow guidance to approximately $2.8 billion, following a 3% growth in orders year-over-year. Furthermore, Emerson has finalized the sale of its remaining 40% stake in Copeland to Blackstone (NYSE:BX), aligning with the company's strategy to focus on its core competencies.

Emerson has also made a strategic investment in Symmera, a company specializing in device authentication and data protection, through its corporate venture capital arm, Emerson Ventures.

Analyst firms, including Stephens, Oppenheimer, Morgan Stanley (NYSE:MS), JPMorgan, and Mizuho (NYSE:MFG) Securities, have adjusted their ratings and price targets for Emerson. These adjustments reflect considerations of Emerson's operational activities, potential future transactions, and the company's financial outlook in light of market conditions.

Notably, Stephens has downgraded Emerson shares from Overweight to Equal Weight, citing the potential impact of the possible acquisition of the remaining shares in Aspen Technology (NASDAQ:AZPN). Oppenheimer, on the other hand, has raised its price target for Emerson shares to $125, reaffirming an Outperform rating on the company. These are recent developments that have taken place in the company.

InvestingPro Insights

Emerson Electric Co.'s recent financial performance, as highlighted in the article, aligns well with several key metrics and insights from InvestingPro. The company's impressive 13% year-over-year increase in quarterly net sales is reflected in its robust revenue growth of 13.34% over the last twelve months, according to InvestingPro data. This growth trend is further supported by a strong gross profit margin of 51.62%, underscoring Emerson's ability to maintain profitability while expanding its sales.

InvestingPro Tips reveal that Emerson has raised its dividend for 53 consecutive years, demonstrating a long-standing commitment to shareholder returns. This is particularly noteworthy given the company's current dividend yield of 1.91%. Additionally, Emerson is recognized as a prominent player in the Electrical Equipment industry, which aligns with its strong market position and the growth in its strategic project funnel mentioned in the article.

For investors seeking more comprehensive analysis, InvestingPro offers 6 additional tips that could provide further insights into Emerson's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.